Tumor Infiltrating Lymphocytes Market Report 2026

Tumor Infiltrating Lymphocytes Market Overview

• Tumor Infiltrating Lymphocytes market size has reached to $12.05 billion in 2025 • Expected to grow to $23.25 billion in 2030 at a compound annual growth rate (CAGR) of 14% • Growth Driver: Surge In Tumor-Infiltrated Lymphocytes (TIL) Market Fueled By Rising Cancer Cases • Market Trend: Strategic Partnerships For Innovative Gene Editing Treatments Propel Tumor-Infiltrating Lymphocyte Market • North America was the largest region in 2025.

What Is Covered Under Tumor Infiltrating Lymphocytes Market?

Tumor infiltrating lymphocytes are immune cells that are able to identify and eradicate cancer cells after entering a tumor via the bloodstream. They are extracted from a patient's tumor, multiplied in large quantities in a lab, and then given back to the person to help the immune system eradicate cancer cells. The main anatomies of tumor-infiltrating lymphocytes include CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, and FOXP3. The cluster of differentiation 3 (CD3) is a multimeric protein complex that was previously known as the T3 complex. The components include T-cells, B-cells, and natural killer cells for applications in melanoma, cervical cancer, ovarian cancer and others. The end-users include hospitals, cancer research centers, and clinics.

What Is The Tumor Infiltrating Lymphocytes Market Growth Forecast?

The tumor infiltrating lymphocytes market size is expected to see rapid growth in the next few years. It will grow to $23.25 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to growing adoption of tumor infiltrating lymphocytes therapies, expansion of cGMP-compliant manufacturing facilities, integration of ai in cell therapy process optimization, rise in strategic partnerships between pharma and biotech, regulatory approvals for novel t-cell therapies. Major trends in the forecast period include personalized cell therapy development, ex vivo t-cell expansion techniques, immunotherapy combination approaches, tumor microenvironment modulation, advanced cell storage & cryopreservation.

What Is The Driver Of The Tumor Infiltrating Lymphocytes Market?

The rising number of cancer patients is expected to propel the growth of the tumor infiltrated lymphocytes (TIL) market going forward. Cancer is a condition in which some cells in the body develop uncontrollably and spread to other regions of the body, leading to a range of health issues, some of which can be fatal. Tumor-infiltrating lymphocytes are a type of immune cell that can detect and destroy cancer cells. Tumor-infiltrating lymphocytes are extracted from a patient's tumor and grown externally in massive numbers in a laboratory before being infused back into the patient to assist the immune system in killing the cancer cells. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, an Australian-based national agency for information and statistics on Australia's health and welfare, by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024, reflecting the impact of a growing population and rising cancer rates. Additionally, in 2024, cancer is anticipated to account for about 3 out of every 10 deaths in the country. Therefore, the rise in cancer patients will drive the tumor infiltrated lymphocyte market.

Key Players In The Global Tumor Infiltrating Lymphocytes Market

Major companies operating in the tumor infiltrating lymphocytes market are Novartis AG, Pfizer Inc., Precision BioScience Inc., TCR2 Therapeutics Inc., Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Intellia Therapeutics Inc., MaxCyte Inc.

Global Tumor Infiltrating Lymphocytes Market Trends and Insights

Major companies operating in the tumor-infiltrating lymphocyte market are adopting a strategic partnership approach, aiming to develop innovative treatments that control gene editing. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in February 2023, Moderna, a US-based pharmaceutical and biotechnology company, entered into a strategic collaboration with Life Edit Therapeutics, a US-based next-generation genome editing company, to accelerate the development of novel in vivo gene editing therapies. This partnership aims to leverage Moderna's mRNA technology alongside Life Edit's proprietary genome editing platform to create more effective and precise therapies for various diseases, including cancer and genetic disorders. The collaboration reflects a growing trend in the biopharmaceutical industry to combine innovative technologies for advanced therapeutic solutions.

What Are Latest Mergers And Acquisitions In The Tumor Infiltrating Lymphocytes Market?

In May 2023, Phio Pharmaceuticals, a US-based biotechnology company, collaborated with AgonOx Inc. to treat cancer patients to advance the development of innovative tumor-infiltrating lymphocyte (TIL) therapies. This partnership aims to leverage Phio's proprietary technology in engineered TILs alongside AgonOx's expertise in immuno-oncology, potentially leading to enhanced treatment options for patients with solid tumors. AgonOx Inc. is a US-based company that develops novel therapies to treat cancer patients.

What Defines the Tumor Infiltrating Lymphocytes Market?

The tumor infiltrating lymphocytes market consists of sales of autologous TILs (tumor infiltrating lymphocytes), allogeneic TILs, and engineered TILs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tumor Infiltrating Lymphocytes Market Report 2026?

The tumor infiltrating lymphocytes market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tumor infiltrating lymphocytes industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.